Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Auxilium Pharmaceuticals soared over 10% this morning after Endo International plc upped its unsolicited tender offer to buy the company by $400 million, for a grand total of $2.6 billion or $33.25 per share. As a refresher, Endo's initial offer on Sept. 17 was $2.2 billion, or $28.10 per share. Auxilium subsequently rejected the offer as being "too low".
Per the press release, Auxilium's board has reportedly approved this higher offer, but shareholders will get the final say in an upcoming vote. If the deal goes through, it would come at a 55% premium compared to where Auxilium shares were trading prior to Endo's original tender offer roughly a month ago.
So what: Auxilium's portfolio of urology and men's health products have had a rough year sales-wise, led by declining sales of its testosterone gel Testim. After a planned restructuring process, experts are expecting the company to return to growth in a big way, with earnings per share projected to more than quintuple from current levels next year.
Now what: Auxilium shareholders have a couple of options in terms of how this deal would be structured, if they elect to approve it. Specifically, they can select an all-cash, all-stock or cash-and-stock payment, according to reports.
Will this deal go through? It's looking more likely this time around. As I mentioned previously, Endo's initial offer did appear to be low, given Auxilium's strong growth prospects moving forward. With this higher bid and Auxilium choosing to nix its buyout of Canadian biotech QLT last Friday, I think all systems are now a go. Perhaps most importantly, shareholders would get a hefty premium via this revised bid, removing the risk of having to depend on organic growth next year.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today originally appeared on Fool.com.George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.